Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes

Status Recruiting

Clinical Trial Summary

To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis.

Clinical Trial Description

Very few human data are currently available on the fatty acid composition of cardiomyocytes membranes. Preoperative omega-3 supplementation for patients undergoing cardiac surgery with cardiopulmonary bypass is correlated with a decreased frequency of postoperative complications in type of arrhythmia atrial fibrillation. Atrial fibrillation is the most common complication: 30 to 50% after myocardial revascularization. The occurrence of atrial fibrillation increases morbidity and mortality after surgery for sure. The pathophysiological mechanisms of common atrial fibrillation treated in heart rhythm units are different from those of postoperative atrial fibrillation. Indeed, atrial fibrillation is a common disease primarily of the left atrium, although atrial fibrillation after cardiac surgery is a multifactorial disease with implication of various pathogens such as inflammation without precise anatomical support. The preventive use of polyunsaturated fatty acids omega-3 long-chain (LC-AGPIω3), prior cardiac surgery is far from widespread due to a Lack of information dissemination, by insufficient number of published studies, despite the existence of a number of ongoing clinical trials and a complete ignorance of biological mechanisms of action. A human clinical study is needed. In a context of cardiac surgery with cardiopulmonary bypass and without deleterious side effects of preoperative enrichment in omega-3, it seems appropriate to conduct a feasibility study to provide information on structural changes in membranes of cardiomyocytes. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01699230
Study type	Interventional
Source	University Hospital, Clermont-Ferrand
Contact	Patrick LACARIN
Phone	04 73 75 11 95
Email	placarin@chu-clermontferrand.fr
Status	Recruiting
Phase	Phase 3
Start date	March 2011
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02335086` - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	N/A
Withdrawn	`NCT02265146` - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed	`NCT00811772` - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis	N/A
Recruiting	`NCT03322332` - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries	N/A
Completed	`NCT02305953` - Cytokines and Vascular Inflammation in Psoriasis	N/A
Completed	`NCT01642173` - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography	Phase 1
Completed	`NCT02316782` - Bifurcation Lesion Analysis and STenting / BLAST	N/A
Completed	`NCT00548613` - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium	Phase 1
Terminated	`NCT00243308` - Serp-1 for the Treatment of Acute Coronary Syndrome	Phase 2
Recruiting	`NCT05105750` - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis	Phase 4
Completed	`NCT01722214` - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis	Phase 4
Terminated	`NCT01030328` - AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis	Phase 3
Suspended	`NCT00790764` - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)	Phase 2
Active, not recruiting	`NCT01061398` - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification	N/A
Completed	`NCT00431717` - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes	N/A
Completed	`NCT00431977` - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes	N/A
Recruiting	`NCT00155350` - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients	Phase 4
Recruiting	`NCT05708547` - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated	`NCT02440646` - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Completed	`NCT02576704` - Prognostic Value of Myocardial Perfusion Heterogeneity in Normal SPECT Studies	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis? — CORONOMEGA3

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms